Clinical Trial

A Study of BA1202 in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 25, 2024 (before its estimated February 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, open-label, single-arm phase I study in patients with advanced solid tumors which consists of a dose escalation part (Part A) and a dose extension part (Part B). Part A aims to evaluate the safety and tolerability of BA1202, and determine the MTD. Part B will also evaluate the preliminary efficacy of BA1202.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-06-09; most recent amendment 2024-04-24.
Status change: Not Yet Recruiting → Recruiting 2024-04-24
Trial Details
NCT Number NCT05909241
Lead Sponsor Shandong Boan Biotechnology Co., Ltd
Conditions Advanced Solid Tumor
Enrollment 78 participants
Start Date 2023-08-16
Primary Completion 2025-02 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-04-25